To maximize the specific uptake into the BC cells/tissues as well as to avert non-target accumulation, many researchers have adapted active targeting strategy in which Cur-nanomedicines were conjugated with diverse targeting ligands (e.g., FA, transferrin, PDL-1, hyaluronic acid, monoclonal antibody, affibody, etc.). This evidence concerns the gene CD274 and breast cancer.